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Abstract 
Purpose: The only curative treatment of Fanconi anemia is hematopoietic stem 
cell transplantation, which has a higher rate of successful outcome when donors 
are compatible siblings. For this reason, a number of families opt to have a 
healthy and compatible baby after embryo selection by preimplantation genetic 
diagnosis with HLA typing to generate a donor for an affected sibling. The aim 
of this study is to provide an estimate of the success rate of this procedure from 
the family’s perspective.  
Methods: Forty two in vitro fertilization cycles were followed, with detailed 
genetic and embryology data from 38 cycles. Genetic reports with detailed 
embryology and genetic data per cycle were provided by the families for this 
study.  
Results: From a total of 524 oocytes (14.1 oocytes per cycle), 299 embryos 
were generated (8.0 embryos per cycle) of which 16 were transferred to the 
uterus as they were non FA and HLA-matched. One baby was finally born. A 
younger couple delivered a healthy and HLA compatible baby after 4 cycles. 
Therefore, the success rate per cycle is below 5% (2 savior babies from 42 
trials).   
Conclusion: While FA per se does not worsen the probabilities of success, the 
critical factor in these families is advanced maternal age due to late diagnosis of 
FA leading to few non-FA and HLA-matched embryos and high aneuploidy rate. 
The families should be informed in advance of the many trials that they will 
probably need to undergo even if a haploidentical younger female relative is 
available as oocyte donor.  
 
Introduction 
The only curative treatment for many blood disorders is hematopoietic stem cell 
transplantation (HSCT), which has a higher rate of successful outcome when 
the donors are compatible siblings. For this reason, a number of affected 
families opt to have an HLA-compatible baby through embryo selection by 
preimplantation genetic diagnosis (PGD) with HLA typing1 (PGD+HLA) in order 
to generate a donor for an affected child. In fact, this procedure was initially 
developed to provide a donor for a Fanconi anemia (FA) patient, and was later 
applied to other blood disorders when transplantation is non-urgent and parents 
are of reproductive age2,3. FA is a rare genetic syndrome characterized by bone 
marrow failure, congenital malformations, chromosome fragility, and cancer 
predisposition. Mutations in 16 genes (FANCA, B, C, D1, D2, E, F, G, I, J, L, M, 
N, O, P, and Q) are known to cause FA, including one recently identified by our 
team via whole exome sequencing4. Early genetic subtyping and mutational 
analysis of this and related disorders are extremely important, not only for 
proper diagnosis, genetic counseling, and management, as for any genetic 
disease, but also for the implementation of curative therapies including HSCT 
following embryo selection.  
 
Most of the news and literature available on the topic of PGD and savior babies 
comes from in vitro fertilization (IVF) clinics with a potential bias towards 
positives outcomes given that unsuccessful trials are often not reported or 
announced in the mass media. As co-coordinator of the Spanish FA Research 
Network and reference laboratory in the genetic diagnosis of Spanish FA 
patients5, we are in contact with all Spanish FA families willing to undergo 
embryo selection. The aim of this study is to provide FA families and their 
clinicians and genetic counselors with an estimate of the success rate of this 
procedure from the family’s perspective. For this purpose, we systematically 




In this study we followed 8 Spanish families with FA complementation group A 
(FANCA) over a period of 11 years. To avoid any selection bias, we included all 
FA families undergoing PGD with HLA typing without any selection based on 
procedure success, maternal age or gene. Collectively, these 8 families carried 
out 42 PGD+HLA typing selection trials. To our knowledge, this is the largest 
series of PGD+HLA individual cycles ever reported for FA. All cycles were 
performed in specialized reproductive clinics in the USA, Belgium, and Spain. 
The IVF reports with detailed embryology and genetic data per cycle were 
provided by the families for this study. The data collected was maternal age, 
number IVF cycles performed, number of oocytes retrieved per cycle, number of 
embryos obtained in each cycle, number of non-FA embryos (either carriers or 
non carriers of FANCA mutations), number of transferrable embryos (non-FA 
and HLA-matched), and number of transferred embryos. We followed up all the 
families to know the number of pregnancies and abortions, and number of 
babies born. Aneuploidy data was also collected from the genetic reports when 
available. Aneuploidy was tested by FISH, PCR, or aCGH depending on the 
date of the IVF cycle and the reporting IVF clinic.   
 Results 
Of the 8 families and 42 IVF cycles followed in this study, detailed data on 
PGD+HLA procedures are available for 38 cycles in 7 families, with a maternal 
age of 39.3 ± 1.8 (range 37–41) (Table 1). As graphically shown in Fig. 1, from 
a total of 524 oocytes (14.1 ± 7.9 per cycle), 299 embryos (8.0 ± 6.1 per cycle) 
were generated by intracytoplasmic sperm injection. Of the embryos for which 
single blastocytes could be analyzed, 75 were non FA (including monoallelic 
carriers or non-carriers), 26 were non FA and HLA compatible, and 16 could be 
transferred to the uterus. Five pregnancies occurred (confirmed by ultrasound 
and hormonal testing), but only one baby was born. Therefore, the success rate 
per IVF cycle was 2.6% (1 baby born from 38 trials), and the live birth rate per 
embryo transferred was 6.25% (1 baby born from 16 embryos transferred). 
When considering the 8th family, who had a baby after 4 cycles, the success 
rate was still very low: 2 babies born from 42 trials (4.8%). However, it is 
important to highlight that this mother was 25 years old, which is much younger 
than the rest of the mothers included in this study. 
 
The causes of the 4 documented abortions in this study are unknown. In 
addition to FA and HLA genetic status, 28 embryos were concurrently tested for 
chromosomal numerical abnormalities by FISH, PCR, or aCGH. In most cases, 
not all 23 chromosomes were assayed; however, 15 out of 28 embryos (53.6%) 
were found to be aneuploid, including a monosomy 6 that was indirectly 
detected in 1 embryo as a result of abnormal HLA markers. Of the 4 embryos 
that resulted in spontaneous abortion, none underwent aneuploidy testing. 
However, given the advanced maternal age, the probability that these embryos 
were aneuploid for any of the 23 chromosomes is extremely high.  
 
Discussion 
In addition to the known low Mendelian probability (only 3 out 16 embryos are 
theoretically expected to be non FA and HLA-matched), there are a number of 
other factors that may lead to the observed low success rate. These include a 
low initial number of embryos; loss of embryos during culture, manipulation, and 
selection procedures; a low implantation rate; a low live birth rate per embryo 
transferred; and a high incidence of miscarriages most probably due to 
aneuploidy specially at advanced maternal age. In our cohort of FA families, the 
mean number of oocytes retrieved (14.1 per cycle), embryos (8 per cycle) and 
aneuploid embryos (53.6%) obtained is similar to that reported in larger non FA 
PGD cohorts of similar maternal age (39-40 years old)6. This observation 
suggests that the FA disease, per se, does not worsen the success rate of 
savior baby generation. The critical point in FA seems to be advanced maternal 
age. Unfortunately, advanced maternal age is unavoidable in most FA cases, 
given that the diagnosis of FA is rare in newborns. In fact, the mean age of 
onset of the hematological disease in FA is 7 years5,7, and the majority of 
patients are diagnosed months to years after onset. 
 
Given that an advanced maternal age negatively affects the success rate of 
IVF, one Spanish FA family who had unsuccessfully performed 4 IVF cycles 
(couple 6 in table 1) opted to use a haploidentical maternal cousin as an oocyte 
donor. The cousin was 10 years younger than the biological mother and was 
not a carrier of the maternal mutation. In total 3 cycles were performed. No 
pregnancy occurred after the 2 first PGD+HLA trials. In the first trial, 2 out of 4 
embryos were HLA-compatible, but 1 of these was determined by aCGH to be 
aneuploid. The matched embryo with normal ploidy was transferred to the 
uterus; however, no pregnancy occurred. In the second trial, only 2 embryos 
were analyzed for HLA, carrier status, and aneuploidy. Neither of these 
embryos was HLA-matched with the FA patient. In the third trial, 8 embryos 
were biopsied. Seven were not mutation carriers of which 5 were HLA-matched, 
and 3 of them were not aneuploid by aCGH. One non-FA, non-aneuploid and 
HLA-matched embryo was initially transferred to the uterus but it did not 
implant. The 2 remaining non-FA, non-aneuploid and HLA-matched embryos 
were transferred one month later and both implanted. The pregnancy with two 
fetal sacs currently goes on normally at week 21 (December 1st). This family’s 
experience demonstrates the extreme difficulties that can arise during attempts 
to generate a savior baby. Three other families in our study underwent 10, 7, 
and 7 unsuccessful trials. Therefore, clinicians and FA families considering 
PGD+HLA must make informed decisions, taking into account that probably 
more than 95% of the IVF cycles will not result in a birth and that the probability 
worsens as the age of the mother approaches 40 years. Knowledge of the 
success rates is important for the families, not only in psychological terms but 
also for economic reasons, as PGD+HLA trials in private reproductive clinics 
can be extremely expensive for the family or the public health system. In 
addition, the families should be aware in advance of the many trials that they 
will probably need to undergo even if a haploidentical female relative is 
available as younger oocyte donor. 
 Despite the low success rate of savior baby generation, the outlook for FA 
patients has been improved by several recent advances. The clinical outcome 
of transplantation in FA using HLA-matched non-siblings as HSC donors has 
greatly improved in the last few years because of optimized HSCT drugs and 
protocols8. Additionally, FA gene therapy clinical trials are currently underway9. 
Finally, disease-free blood progenitors from skin fibroblasts of FA patients were 
recently generated via induced pluripotent stem cells, setting the path for a 
future cure through regenerative medicine for patients with FA and other blood 
disorders10-12. We hope that these therapeutic advances will make the 
generation of savior babies to cure FA and other blood genetic disorders 
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Table 1: Data from 38 PGD+HLA typing IVF cycles in 7 Fanconi anemia families 
 
Couple number 
   
 
1 2 3 4 5 6 7 
 
mean SD 
FA gene mutated A A A A A A A 
   
Maternal age (years) 37 42 38 38 40 41 39 
 
39.3 1.8 
Number of IVF cycles 6 7 2 10 7 4 2 
 
5.3 2.9 
Oocytes retrieved 60 59 37 236 92 34 6 
 
14.1* 7.9* 
Embryos 38 26 18 158 32 22 5 
 
8.0* 6.2* 
Non FA embryos** 15 7 9 22 10 9 3 
 
2.2* 1.8* 
Transferrable embryos 3 3 3 10 4 2 1 
 
0.8* 0.8* 
Embryos transferred 2 1 1 7 3 1 1 
 
0.5* 0.6* 
Pregnancies 2 0 1 0 0 1 1 
 
0.2* 0.3* 
Babies born 0 0 1 0 0 0 0 
 
0.03* 0.2* 
*Mean and SD (standard deviation) per cycle of all 38 individual IVF cycles 
**Includes monoallelic carriers or non carriers of FANCA mutations  
Legend to figure 1: 
Graphical representation of accumulated embryology and genetic data from 38 PGD 
with HLA typing IVF cycles in 7 Fanconi anemia families 
 
